Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism
- 1 June 2018
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Lipidology
- Vol. 29 (3), 171-179
- https://doi.org/10.1097/mol.0000000000000502
Abstract
Apolipoprotein (apo) C-III is a key player in triglyceride-rich lipoprotein metabolism and strongly associated with elevated plasma triglyceride levels. Several new studies added important insights on apoC-III and its physiological function confirming its promise as a valid therapeutic target. APOC3 is expressed in liver and intestine and regulates triglyceride-rich lipoprotein (TRL) catabolism and anabolism. The transcriptional regulation in both organs requires different regulatory elements. Clinical and preclinical studies established that apoC-III raises plasma triglyceride levels predominantly by inhibiting hepatic TRL clearance. Mechanistic insights into missense variants indicate accelerated renal clearance of apoC-III variants resulting in enhanced TRL catabolism. In contrast, an APOC3 gain-of-function variant enhances de novo lipogenesis and hepatic TRL production. Multiple studies confirmed the correlation between increased apoC-III levels and cardiovascular disease. This has opened up new therapeutic avenues allowing targeting of specific apoC-III properties in triglyceride metabolism. Novel in vivo models and APOC3 missense variants revealed unique mechanisms by which apoC-III inhibits TRL catabolism. Clinical trials with Volanesorsen, an APOC3 antisense oligonucleotide, report very promising lipid-lowering outcomes. However, future studies will need to address if acute apoC-III lowering will have the same clinical benefits as a life-long reduction.This publication has 80 references indexed in Scilit:
- Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and HumansCirculation Research, 2013
- Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycansJCI Insight, 2013
- Probing isoform-specific functions of polypeptide GalNAc-transferases using zinc finger nuclease glycoengineered SimpleCellsProceedings of the National Academy of Sciences of the United States of America, 2012
- Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII, and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemiaJournal of Clinical Lipidology, 2011
- Heterozygosity for a Loss-of-Function Mutation in GALNT2 Improves Plasma Triglyceride Clearance in ManCell Metabolism, 2011
- Missense Mutation in APOC3 within the C-terminal Lipid Binding Domain of Human ApoC-III Results in Impaired Assembly and Secretion of Triacylglycerol-rich Very Low Density Lipoproteins: EVIDENCE THAT ApoC-III PLAYS A MAJOR ROLE IN THE FORMATION OF LIPID PRECURSORS WITHIN THE MICROSOMAL LUMEN*Online Journal of Public Health Informatics, 2011
- Regulation of Hepatic ApoC3 Expression by PGC-1β Mediates Hypolipidemic Effect of Nicotinic AcidCell Metabolism, 2010
- A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent CardioprotectionScience, 2008
- Familial Deficiency of Apolipoproteins A-I and C-III and Precocious Coronary-Artery DiseaseThe New England Journal of Medicine, 1982
- Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoproteinBiochemical and Biophysical Research Communications, 1972